Drug Profile


Alternative Names: TAK-438; TAKECAB; VONOPION® pack; Vonoprazan fumarate; VONOSAP® pack 400; VONOSAP® pack 800

Latest Information Update: 22 May 2017

Price : $50

At a glance

  • Originator Takeda
  • Class Amines; Antiulcers; Pyridines; Pyrroles; Small molecules; Sulfonamides
  • Mechanism of Action Potassium-competitive acid blockers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Duodenal ulcer; Erosive oesophagitis; Gastric ulcer; Gastro-oesophageal reflux; Helicobacter infections; Peptic ulcer; Reflux oesophagitis

Most Recent Events

  • 25 Apr 2017 Takeda initiates a phase I pharmacokinetics trial in Healthy volunteers in China (NCT03085836)
  • 23 Mar 2017 Takeda plans a phase I pharmacokinetics trial in Healthy volunteers in China (NCT03085836)
  • 14 Feb 2017 Takeda plans a phase III trial for Gastric ulcer in China, Korea, Taiwan and Philippines (NCT03050307)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top